




The relative strengths and weaknesses of Epirus Biopharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epirus Biopharmaceuticals Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 3.5% points. The greatest weakness of Epirus Biopharmaceuticals Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 102% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	20,742
Cost of Goods Sold	0
Intangible Assets	7,200
Liabilities, Current	14,892
Liabilities, Non-Current	0
Other Assets	1,801
Other Compr. Net Income	-10
Other Expenses	11,921
Other Liabilities	0
Other Net Income	60
Other Revenues	14,731
Property and Equipment	2,363
Research and Development	33,964
Selling, General and Administrative Expense	7,523

Output Variable	Value in 1000 USD
Assets	32,106
Liabilities	14,892
Expenses	53,408
Revenues	14,731
Stockholders Equity	17,214
Net Income	-38,617
Comprehensive Net Income	-38,622
BaseVar	57,604
ECR before LimitedLiability	-4.7%
Economic Capital Ratio	141%